ORIC Pharmaceuticals Inc. (ORIC)
ORIC Pharmaceuticals Statistics
Share Statistics
ORIC Pharmaceuticals has 71.09M shares outstanding. The number of shares has increased by 5.35% in one year.
| Shares Outstanding | 71.09M |
| Shares Change (YoY) | 5.35% |
| Shares Change (QoQ) | 0.65% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,567 |
| FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 13.26M, so 18.65% of the outstanding shares have been sold short.
| Short Interest | 13.26M |
| Short % of Shares Out | 18.65% |
| Short % of Float | 18.98% |
| Short Ratio (days to cover) | 14.08 |
Valuation Ratios
The PE ratio is -4.4 and the forward PE ratio is -2.93. ORIC Pharmaceuticals's PEG ratio is 0.66.
| PE Ratio | -4.4 |
| Forward PE | -2.93 |
| PS Ratio | 0 |
| Forward PS | 8.1 |
| PB Ratio | 2.31 |
| P/FCF Ratio | -4.99 |
| PEG Ratio | 0.66 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ORIC Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.56, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.56 |
| Quick Ratio | 10.56 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,111,713.04 |
| Employee Count | 115 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -41.49% in the last 52 weeks. The beta is 1.37, so ORIC Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.37 |
| 52-Week Price Change | -41.49% |
| 50-Day Moving Average | 6.4 |
| 200-Day Moving Average | 8.84 |
| Relative Strength Index (RSI) | 49.6 |
| Average Volume (20 Days) | 1,049,562 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -142.9M |
| Net Income | -127.85M |
| EBITDA | -142.9M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.83 |
Balance Sheet
The company has 59.41M in cash and 3.18M in debt, giving a net cash position of 56.22M.
| Cash & Cash Equivalents | 59.41M |
| Total Debt | 3.18M |
| Net Cash | 56.22M |
| Retained Earnings | -562.77M |
| Total Assets | 274.14M |
| Working Capital | 237.4M |
Cash Flow
In the last 12 months, operating cash flow was -112.66M and capital expenditures 0, giving a free cash flow of -112.66M.
| Operating Cash Flow | -112.66M |
| Capital Expenditures | n/a |
| Free Cash Flow | -112.66M |
| FCF Per Share | -1.62 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ORIC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ORIC is $20, which is 259.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 259.1% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 3.42 |
| Piotroski F-Score | 2 |